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Evidence is mounting that proinﬂammatory and proapoptotic thioredoxin-interacting protein (TXNIP) has a causative role in
the development of diabetes. However, there are no studies investigating the role of TXNIP in diabetic retinopathy (DR). Here, we
show that, in diabetic rats, TXNIP expression and hexosamine biosynthesis pathway (HBP) ﬂux, which regulates TXNIP, are
elevated in the retina and correlates well with the induction of inﬂammatory cyclooxygenase 2 (Cox-2) and sclerotic ﬁbronectin
(FN). We blocked the expression of TXNIP in diabetic rat retinas by: (i) inhibiting HBP ﬂux; (ii) inducing post-transcriptional gene
silencing (PTGS) for TXNIP mRNA; and (iii) performing an in vivo transcriptional gene silencing (TGS) approach for TXNIP
knockdown by promoter-targeted small interfering RNAs and cell-penetrating peptides as RNA interference (RNAi) transducers.
Each of these methods is efﬁcient in downregulating TXNIP expression, resulting in blockade of its target genes, Cox-2 and FN,
demonstrating that TXNIP has a causative role in aberrant gene induction in early DR. RNAi TGS of TXNIP abolishes diabetes-
inducedretinalgliosisandganglioninjury.Thus,TXNIPhasacriticalroleininﬂammationandretinalinjuryinearlystagesofDR.
The successful employment of TXNIP TGS and amelioration of its pathological effects open the way for novel therapeutic
strategies aimed to block disease onset and progression of DR.
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Diabetic retinopathy (DR) is the leading cause of postnatal
blindness in developed countries and one of the most severe
complications of diabetes.
1 DR is characterized by blood–
retinal barrier breakdown, neovascularization, glial dysfunc-
tionandneuronaldeath.Amongthepathologicalchangesthat
occur early and linked causally to the development of
retinopathy in diabetes are inﬂammation, altered extracellular
matrix (ECM) gene expression, and premature demise of
retinal capillary and ganglion cells.
2–5 However, it is not yet
elucidated which components are most important for disease
initiation and development of DR and which may be most
useful as therapeutic targets. Several studies demonstrated
a pathogenic role of proinﬂammatory and proapoptotic
thioredoxin-interacting protein (TXNIP) in the development
ofbothtypeIandIIdiabetesanditsvascularcomplications.
6–9
TXNIP has been shown to inhibit thioredoxin activity and
reduces cellular antioxidant capacity.
6 Deﬁciency of TXNIP
leads to improved glucose tolerance and insulin sensitivity in
mice fed with a high-fat diet,
7 protects against diabetes
8 and
inhibits glucose-induced pancreatic b-cell apoptosis.
9 TXNIP
induces caspase-1 inﬂammasome and innate immune
response in pancreatic b-cell and macrophage.
10 TXNIP is
also highly induced by diabetes in renal mesangial cells,
11,12
neurons
13 and retinal cells.
14 We reported that TXNIP is
required for RAGE-induced proinﬂammatory gene expression
in retinal endothelial cells (ECs) under diabetic conditions
in vitro and that TXNIP expression is signiﬁcantly elevated in
the diabetic rat retina.
14 However, it is still unknown whether
TXNIP is involved in the development and progression
of diabetic ocular complications. Owing to the emerging
relevance of TXNIP in diabetic complications and the lack
of studies of TXNIP function in DR, we investigated the
molecular mechanisms responsible for hyperglycemia (HG)-
induced TXNIP expression in retinal EC in vitro and whether
TXNIP has a causative role in early diabetic abnormalities
invivointheretinaofstreptozotocin(STZ)-induceddiabeticrats.
We have shown previously that the excess glucose
metabolic ﬂux through the hexosamine biosynthesis pathway
(HBP) mediates cellular oxidative stress, aberrant gene
expression and apoptotic demise of renal mesangial
cells.
15,16 In the HBP, UDP-N-acetyl-glucosamine is the ﬁnal
productandisutilizedasprecursorforglycosylationofvarious
cytoplasmic and nuclear proteins (Supplementary Figure S1).
We reported that the HBP ﬂux has a role in inducing TXNIP
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and diabetic kidney.
11,16 Herein, we investigated whether HG
and diabetes induce TXNIP expression via elevated HBP ﬂux
in EC in culture and in the retina of diabetic rats in vivo.W e
demonstrate that HG and diabetes induce TXNIP expression
in retinal EC and diabetic retinas, which is mediated by HBP
ﬂux and epigenetic mechanisms involving the recruitment
of p300 histone acetyltransferase (HAT) at the TXNIP
promoter.
To analyze whether TXNIP is required for diabetes-induced
early retinopathy, we measured the expression of two genes
that are downstream of TXNIP and relevant to the develop-
ment of DR: (i) cyclooxygenase 2 (Cox-2) that is involved in
inﬂammation
14,17 and (ii) ﬁbronectin (FN) involved in retinal
angiogenesis and ﬁbrosis.
3 Moreover, we investigated
whether TXNIP is associated with diabetes-induced retinal
glia reactivity and neuronal injury. To elucidate the causative
role of TXNIP in DR, we employed several methods to blunt
TXNIP expression including a novel strategy to silence the
expression of TXNIP in vivo by promoter-targeted small
interfering RNA (siRNA) (RNA interference (RNAi))-mediated
transcriptional gene silencing (TGS).
18,19 We show that
TXNIP is required for diabetes-induced Cox-2 and FN
expression, gliosis and neuronal apoptosis in the rat retina,
shedding some light into a crucial role of TXNIP in disease
initiation and progression of early DR.
Results
Diabetes increases retinal HBP ﬂux, TXNIP, Cox-2 and
FN expression. In this study, we investigated whether
TXNIP upregulation in the diabetic rat retina
14 has a critical
role in early abnormalities of DR in vivo. First, we analyzed
whether HBP ﬂux, which activates TXNIP, and TXNIP
expression are enhanced in the diabetic rat retina and
whether they correlate with changes in inﬂammatory Cox-2
and FN expression after 4 weeks of hyperglycemic dura-
tion. Diabetes in rats was induced by STZ and their
characterization is shown in Supplementary Table 1. We
examined the level of HBP in retinal cell extracts from
normal and diabetic rats by determining protein Ser/Thr-O-
GlcNAcylation with CTD110.6 antibodies on western
blots. The results show that diabetes induces retinal
O-GlcNAcylation of several proteins when compared with
the normal retina indicating elevated HBP ﬂux (Figure 1A).
Enhanced HBP parallels TXNIP and Cox-2 expressions both
at protein (Figure 1B) and mRNA levels (Figure 1C). FN
mRNA is also increased in the diabetic rat retina (Figure 1C),
while protein levels appear to increase at the inner limiting
membrane (ILM) and capillaries (Figure 1D).
Retinal inﬂammation and ﬁbrosis evoke glial reactivity and
neuronal injury under various diseases of the eye; therefore,
Figure1 DiabetesincreasesHBP,TXNIPexpression,inﬂammationandﬁbrosis
intheretina.(A,B)Cellularproteinextracts(30mg)wereanalyzedforproteinSeror
Thr-O-GlcNAcylation using CTD110.6 antibodies, which speciﬁcally recognize the
O-GlcNAc moieties, and TXNIP expression on western blots. In addition, Cox-2
expression was also determined. (A) Diabetes induces HBP ﬂux as observed by
enhanced CTD110.6 reactivity in diabetic retina (representative blots from n¼5).
Atpresent,wedonotknowtheidentityoftheseproteins.(B)Similarly,diabetesalso
increases TXNIP protein levels (B3.6±0.5-folds, Po0.01 versus normal retina;
n¼6). Furthermore, Cox-2 level is also induced in the diabetic retina
(B1.67±0.17-folds, Po0.05 versus normal retina, n¼5). Actin is not changed.
(C) RT-qPCR analysis reveals that TXNIP expression is signiﬁcantly increased in
the diabetic retina (8.06±3.18-folds) over normal retina, which correlates with
increases in Cox-2 (3.18±0.49) and FN (5.99±0.78) expressions. The asterisk
symbol represents signiﬁcant change (Po0.01, n¼7) in the diabetic retina when
compared with normal retina. (D) On immunohistology, FN expression is increased
inthebasalmembraneofbloodvesselsinGCLandalsointheILMasshownbythe
arrows. A representative of n¼3 is shown. (E) Diabetes induces glial reactivity and
ganglioninjuryinearlyDR.ImmunohistologyanalysisrevealsthatGFAPexpression
isincreasedinthediabeticretina(a,b),whichcorrelateswithcaspase-3activationin
thediabeticretinaasdemonstratedbypositivestainingforFlivo,aninvivoactivated
caspase-3bindingﬂuorescentprobe(c,d,arrow).Nisslstainingwasusedtoidentify
neurons in ﬂat mount retina. These results show that retinal neuronal dysregulation
occur early in the retina of diabetic rats (these results are representative of three
independent experiments)
TXNIP mediates early abnormalities of diabetic retinopathy
L Perrone et al
2
Cell Death and Diseasewe measured the expression of glial ﬁbrillary acid protein
(GFAP), a marker for gliosis, in intermediate ﬁlaments in the
diabetic retina. Results show that GFAP staining increased in
the diabetic retina (Figure 1E, a and b), suggesting glia
activation at early DR. Activation of caspase-3 is also seen in
the ganglion cell layer (GCL) in retinal ﬂat mounts pointing to
programmed cell death (Figure 1E, c and d). Furthermore, a
reduction in presynaptic vesicular protein synapsin 1 expres-
sion occurs in the diabetic retina (Supplementary Figure S2).
These results show that HBP and TXNIP are increased in
diabetic retinas and correlate with retinal inﬂammation,
ﬁbrosis/gliosis and neuronal injury, the distinguishing features
of early DR.
HBP is responsible for HG-induced TXNIP expression in
retinal EC in culture. To ascertain that HBP is involved
in diabetes-induced TXNIP and proinﬂammatory gene
expression in the retina, we ﬁrst investigated the metabolic
pathway and the molecular mechanisms responsible for
HG-induced TXNIP expression in retinal EC in vitro.
We examined whether agents that increase or decrease
the HBP alter HG-mediated TXNIP expression in a rat retinal
EC, TR-iBRB2.
14 We used azaserine to block HBP ﬂux and
glucosamine (GlcN) or PUGNAc to enhance the HBP. The
data show that TXNIP is an early-response gene to HG and
its mRNA expression is induced approximately eightfolds
versus LG, within 2h in TR-iBRB2 cells (Figure 2A, lanes 1
and 2). Pre-incubation of the cells with azaserine blocks
HG-induced TXNIP mRNA expression (Figure 2A, lane 3),
whereas GlcN and PUGNAc stimulate TXNIP expression
(Figure 2A, lanes 4 and 5). HG also increases TXNIP protein,
which is blocked by azaserine (Figures 2B and C), showing
that HBP mediates TXNIP expression in EC.
As HG alters epigenetic chromatin remodeling,
20,21 we also
examined whether 5-aza-cytidine (5-AzaC), an inhibitor of
DNA methyltransferase, or trichostatin A (TSA), an inhibitor
histone deacetylase, has an effect on TXNIP expression.
TR-iBRB2 cells were incubated with 5-AzaC for 24h or with
TSA for 2h. 5-AzaC does not have an effect on TXNIP
expression, whereas TSA increases TXNIP mRNA level
(Supplementary Figure S3A, lane 3). When 5-AzaC and
TSA are present together, TXNIP expression is not further
Figure 2 HBP ﬂux mediates HG-induced TXNIP expression by inducing histone acetylation and p300 recruitment on TXNIP promoter. (a) TXNIP mRNA expression was
analyzed by RT-qPCR using b-actin as a control gene for normalization. Cells were treated for 2h with LG (5mM glucose), HG (25mM glucose), PUGNAc (100mM), GlcN
(1.5mM) and the HBP inhibitor azaserine (0.5mM). Azaserine completely blocks the HG-induced TXNIP expression to the level of LG conditions and the decrement is
statistically signiﬁcant (Po0.01 HG versus HGþazaserine). GlcN and PUGNAc, which increases the HBP by inhibiting O-GlcNAcase removes O-GlcNAc, also enhance
TXNIP expression signiﬁcantly (Po0.01 versus LG). These data are the average of three independent experiments carried out in triplicate (n¼9). (b) Western blot analysis
of TXNIP expression in LG and HG conditions both in the presence and the absence of Azaserine. These data are representative of six independent experiments.
(c)Quantiﬁcationof thewestern blot shown in(b). *Signiﬁcantincrease versusLG (Po0.01); **signiﬁcantdecreaseby azaserineversus HG (Po0.001).(d, e) ChIP analysis
ofhistoneH4lysine(K)8acetylationonTXNIPpromoter.(d)QuantitativePCRand(e)semiquantitativePCRanalysisshowthatHGandTSAinducetheacetylationofhistone
H4K8 on TXNIP promoter (n¼6, *Po0.05 versus mock; **Po0.001 versus LG); (f, g) ChIP analysis of p300 association to TXNIP promoter. (f) Quantitative PCR and (g)
semiquantitative PCR analysis show that HG and GlcN induce the binding of p300 on TXNIP promoter, whereas azaserine blocks HG effects, (n¼6, *Po0.001 versus LG)
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Cell Death and Diseaseenhanced as compared with TSA treatment alone (Supple-
mentary Figure S3A, lane 4). These results indicate that
TXNIP expression depends on histone acetylation and not on
DNA methylation under these conditions.
We next investigated whether HG induces chromatin
remodeling at the TXNIP promoter by chromatin immunopre-
cipitation (ChIP) assay, using an anti-acetylated lysine 8 of
histone 4 (AcH4K8) antibody, an indicator of gene activation.
HG and TSA increase H4K8 acetylation of the TXNIP
promoter (Figures 2D and E, lanes 3 and 4). Enhanced
H4K8 acetylation may be because of the recruitment of
transcriptional cofactors that possess HAT activity, such as
p300. We analyzed the association of p300 at the TXNIP
promoter in EC by ChIP with an anti-p300 antibody followed
byquantitativeandsemiquantitativePCR.P300bindingtothe
TXNIP promoter is low at LG (Figures 2E and F, lane 2);
however, HG treatment induces p300 binding to the TXNIP
promoter (Figures 2E and F, lane 3) and abolishes by
azaserine (lane 4). GlcN also induces p300 binding to the
TXNIP promoter at a level comparable to HG (Figures 2E and
F, lanes 4 and 5). These results show that TXNIP mRNA
induction involves p300 recruitment and histone acetylation at
its promoter.
TXNIP is required for hexosamine-induced FN and
Cox-2 mRNA expression in retinal EC in vitro. We have
previously shown that elevated HBP ﬂux and TXNIP
upregulate FN expression in renal mesangial cells.
11
Therefore, we hypothesized that TXNIP is also necessary
for HBP-induced FN and Cox-2 expression in retinal EC. We
generated TR-iBRB2 cell lines that stably express siRNAs
targeted to TXNIP mRNA and control cells with a scramble
siRNA.
14 Addition of GlcN to scramble siRNA cells for 2h
induces FN and Cox-2 mRNA expression (Supplementary
Figure S4A). GlcN failed to induce FN and Cox-2 mRNA
expressions in siTXNIP cells (Supplementary Figure S4A),
showing that TXNIP is required for GlcN induction of FN and
Cox-2 in EC. Conversely, TXNIP signiﬁcantly induces FN
and Cox-2 mRNA expression in human TXNIP cDNA
(hTXNIP)-overexpressing cells compared with LacZ control
cells (Supplementary Figure S4B). Thus, the data support
our hypothesis that HG-mediated FN and Cox-2 in retinal
cells is mediated at least in part by the HBP and TXNIP.
TXNIP is a mediator HBP-induced inﬂammation and
ﬁbrosis in diabetic rat retinas. We showed above that
HBP is a mediator of HG-induced TXNIP and proinﬂam-
matory gene expression in retinal EC (Figures 2A, B and
Supplementary Figure S4). Therefore, we investigated
further in diabetic retinas in vivo whether the observed HBP
ﬂux (Figure 1A) mediates TXNIP and proinﬂammatory gene
expression. Diabetes enhances O-GlcNAc staining parti-
cularly in the inner plexiform layer (IPL) and around
the nucleus in inner nuclear layer (INL) (Figure 3A, middle
panel, arrows). Azaserine treatment blocks diabetes-induced
increased O-GlcNAc modiﬁcations (Figure 3A, right panel).
TXNIP staining is increased in all areas of the retina, at
highest level in the GCL, IPL and INL when compared with
the normal retina (Figure 3B, left and middle panels).
Azaserine blocks diabetes-induced TXNIP expression
(Figure 3B, right panel), demonstrating that the HBP
mediates TXNIP expression in vivo in the retina. Azaserine
also reduces Cox-2 and FN mRNA levels (Figure 3C).
Further, azaserine also reduces GFAP immunostaining in the
diabetic retina when compared with saline-treated diabetic
eyes (Figure 3D).
Azaserine is an analog of glutamine; therefore, it may also
inﬂuence other enzymatic pathways that require glutamine,
such as glutaminase, affecting TXNIP and its downstream
targets. Therefore, to demonstrate that TXNIP upregulation in
the retina is indeed responsible for proinﬂammatory and
ﬁbroticgeneexpressioninearlyDR,weknockeddownTXNIP
by post-translational RNAi (post-transcriptional gene silen-
cing (PTGS)). We injected siRNAs targeted to TXNIP mRNA
twice in the right eye of diabetic rats, at days 23 and 27, and
examined TXNIP, Cox-2 and FN expression at day 30. We
observed a decrement of TXNIP expression upon siRNA
treatmentcomparedwiththescramblesiRNA-treateddiabetic
retina (Figure 4A). Knockdown of TXNIP in the diabetic retina
leads to a signiﬁcant decrement of both Cox-2 and FN mRNA
(Figures 4A and B). In concert, GFAP upregulation is reduced
by TXNIP siRNAs (Figure 4C). These data demonstrate that
TXNIP is required for inﬂammatory Cox-2 and ﬁbrotic FN
expression and gliosis in early DR.
TGS for TXNIP in the diabetic retina reduces
inﬂammation and gliosis. DR is a chronic disease and
requires long-term treatment strategies. We have shown
above that TXNIP is a mediator of retinal inﬂammation,
ﬁbrosis/gliosis and neurovascular injury in diabetes. To
develop a long-term strategy for gene silencing, we tested
the feasibility of a novel TGS method targeting TXNIP in vivo.
We silenced TXNIP in the retina using RNAi TGS via
intravitreal injection of promoter-targeted siRNA complexes
with a cell-penetrating peptide (CPP) called MPG as siRNA
transducers in the right eyes of diabetic rats. As control, a
scramble siRNA/MPG complex was injected in the left eye
of the same animal. Results show that TXNIP mRNA
level is reduced after TXNIP promoter-siRNA treatment
when compared with the scramble siRNA injected eye
(Figure 5Aa). Furthermore, elevated Cox-2 and FN mRNA
levels are reduced in diabetic retinas after TXNIP promoter-
siRNA treatment (Figure 5A, b and c). To conﬁrm the effective-
ness of RNAi-mediated chromatin closing at the TXNIP
promoter, we measured the binding of p300 to the TXNIP
promoter by ChIP. We observed that p300 binding to the
TXNIP promoter is enhanced in the diabetic retina treated
with scramble siRNA when compared with the normal rat
retina, while TXNIP-TGS reduces p300 recruitment to the
TXNIP promoter (Figure 5B). In agreement, TXNIP protein
staining is reduced in the diabetic rat retina upon TXNIP
knockdown by TGS (Figure 5C).
We next investigated whether diabetes-induced gliosis and
apoptosis are inhibited by TXNIP TGS. GFAP expression and
caspase-3 activation are reduced after TXNIP promoter-
siRNA treatment in the diabetic retina when compared with
scramble siRNA treated eyes (Figures 6A–C). Together, the
various approaches of TXNIP ablation in the retina demon-
strate that TXNIP indeed has a critical role in inﬂammation,
gliosis/ﬁbrosis and apoptosis in early stages of diabetes,
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Cell Death and Diseasewhich will ultimately lead to disease onset and progression
of blinding ocular complications.
Discussion
Thisstudyaimstoelucidatetwounexploredquestionsthatare
relevant to the understanding of the molecular mechanisms
that underline the development of DR: (i) analyze the
metabolic pathway and the molecular network responsible
for HG-induced TXNIP expression; and (ii) investigate
whether TXNIP has a causative role in early abnormalities
of DR. We demonstrate that increased HBP ﬂux is a mediator
ofTXNIP expression in retinal EC under high ambient glucose
in vitro and in vivo diabetic retinas and that transcriptional
cofactor p300 is involved in TXNIP expression. Our new
ﬁndings are: (i) p300 recruitment on TXNIP promoter and
histone acetylationare involved inTXNIP expression in retinal
EC;(ii)TXNIPmediatesCox-2andFNexpressionbothinvitro
and in vivo; and (iii) blockade of TXNIP in vivo in the retina
ameliorates diabetes-induced inﬂammation, gliosis/ﬁbrosis
and neuronal apoptosis (summarized in Figure 7).
We provideseveralevidences todemonstratethatHBPﬂux
induces TXNIP expression in retinal EC. Inhibition of HBP by
azaserine abolishes HG-induced TXNIP expression, whereas
compounds that enhance HBP lead to TXNIP induction
(Figures 2A–C). We show that TSA, which inhibits histone
deacetylase, increases p300 recruitment to the TXNIP
promoter and H4 acetylation, which leads to TXNIP expres-
sion. Similarly, RAGE activation by its endogenous ligand
S100B also induces the recruitment of p300 on TXNIP
promoter and H4 acetylation (Supplementary Figure S3B,
C and S3D, E, respectively). We have previously shown
that RAGE activates TXNIP expression in EC.
14 We did not
perform in this study a direct silencing of p300 to implicate
TXNIP expression exclusively because p300 also mediates
HG-induced expression of several genes in ECs.
22 Thus,
blockade of p300 expression itself may not provide a direct
evidence of p300 involvement in TXNIP expression. Instead,
herein we show that TGS of TXNIP abolishes p300 binding to
TXNIP promoter and suppresses TXNIP mRNA and protein
levels. TGS is known to lead to epigenetic chromatin closing
that affect the recruitment of transcriptional factors and
cofactors to target gene promoters.
19 Thus, the results
Figure3 BlockadeoftheHBPbyazaserinepreventsTXNIPexpression,inﬂammationandgliosisinthediabeticretina.Intravitrealinjectionofazaserine,aninhibitorofthe
HBP, in the right eye of diabetic rats reduces protein O-GlcNAcylation (A), which corresponds to a decrease in TXNIP expression in the same retina (B). A representative of
n¼3 is shown here. The left eye of the same diabetic rats was injected with saline and used as the corresponding diabetic control retina. (C) RT-qPCR analysis for TXNIP,
Cox-2 and FN mRNAs shows their elevated levels that are blunted by azaserine. *Signiﬁcant change (Po0.05, n¼6) for diabetic retina (left eye injected with saline) versus
normalretina;
#signiﬁcantdecrease(Po0.05,n¼6)ingeneexpressionafterazaserinetreatment(righteye)whencomparedwithsaline-treatedlefteyesofthesameanimal.
(D). Diabetes induces glial cell reactivity in the retina as demonstrated by increased GFAP expression in intermediate ﬁlaments, which extend from epiretinal membrane to
photoreceptor ONL. Azaserine prevents GFAP expression in the diabetic retina, which is more or less comparable to GFAP levels in normal rat retina. A representative
of n¼3 is shown here
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Cell Death and Diseaseobtained by RNAi TGS in vivo provide further evidence of the
involvement of p300 in TXNIP expression.
To investigate the functional role of TXNIP in early DR, we
employ three methods to suppress TXNIP expression in the
diabetic retina: (i) inhibition of HBP ﬂux byintravitreal injection of
azaserine;(ii)PTGSbysiRNAtargetedtoTXNIPmRNA-coding
region; and (iii) TGS by siRNA targeted to TXNIP promoter.
With the ﬁrst method we conﬁrmed in vivo that HPB ﬂux is
responsible for diabetes-induced TXNIP expression in the
retina. Further, with the PTGS knockdown of TXNIP, we
demonstrate that TXNIP mediates diabetes-induced inﬂamma-
tory and ﬁbrotic gene expression in retinal EC and in vivo in the
retina. Using the TXNIP TGS, we also demonstrate that TXNIP
is essential for diabetes-induced inﬂammation and ﬁbrosis
because speciﬁc depletion of TXNIP in the retina prevents Cox-
2 and FN expression while HG is still present in the animal.
Diabetes induces the formation of superoxide, which
inhibits glyceraldehyde-3-phosphate dehydrogenase and
accumulation of advanced glycation end products, HBP and
PKC activation. These three pathways are reduced by
transketolase activation via its cofactor thiamine and its
analogbenfotiamine.
23–25Interestingly,benfotiaminereduces
HG-induced nuclear localization of FOXO1,
24 a transcription
factor that promotes TXNIP expression.
26 Thus, benfotiamine
may ameliorate DR pathogenesis via inhibition of both HBP
ﬂux and FOXO1 signaling. Our results further support that
blockade of the HBP ﬂux and TXNIP reduces inﬂammatory
gene expression in early DR. FN is also upregulated in initial
stages of diabetes (4 weeks) at the ILM and vessel basement
membrane in vivo, a characteristic for early vascular
abnormalities in DR. These data are consistent with ﬁndings
from other laboratories that ECM proteins are increased in
DR and cause blood vessel dysregulation.
27 Furthermore,
TXNIP mediates neuronal apoptosis (caspase-3 activation)
and gliosis (GFAP upregulation) in the diabetic rat retina (this
study), which is considered as an early sign of retinal injury
and disease onset.
2,5 TXNIP expression has been shown to
increase in the brain of diabetic animals
28 and it has a critical
role in ganglion cell injury in glaucoma.
29 Gliosis may be
protective in acute retinal injuries to establish tissue home-
ostasis; however, persistent gliosis will cause inﬂammation
and neurotoxicity in chronic diseases such as DR. Our data
clearly support a crucial role of TXNIP in retinal inﬂammation,
gliosis/ﬁbrosis and neuronal injury/apoptosis in diabetes.
Still today, the treatment options for chronic ocular
complications are limited due to the lack of safe delivery
systems to target the retina. Frequent intravitreal injection of
drugs increases the incidence of retinal infection and
intraocular pressure leading to secondary complications.
Therefore, a strategy for long-term gene and drug therapy
for ocular disease treatment is important. With this view in
mind, we undertook the RNAi-mediated epigenetic TGS for
TXNIP silencing in vivo. The molecular mechanisms respon-
sible for TGS have been described.
19,30,31 RNAi TGS leads
to chromatin closing at the targeted promoter via H3K9
dimethylation and subsequent CpG DNA methylation.
Epigenetic gene regulation is mitotically stable and lasts long;
and is therefore most desirable for long-term suppression of
disease-associated genes in chronic inﬂammatory diseases,
including DR. In our design of promoter-targeted siRNA to
silence TXNIP, we selected two sites, which contain an E-box
(Promoter target 1) and a FOXO1 site (Promoter target 2),
which are important for TXNIP expression. We have not
yet investigated whether each siRNA duplex is capable
Figure 4 TXNIP is required for diabetes-induced Cox-2, FN and GFAP expression in the retina. Intravitreal injection of siRNA targeted to TXNIP mRNA (PTGS) on the
right eye, whereas the left eye was injected with scramble siRNA as control. (a–c) RT-qPCR analysis for (a) TXNIP, (b) Cox-2 and (c) FN mRNAs shows their elevated levels
that are blunted by TXNIP PTGS. *Signiﬁcant change (Po0.05, n¼6) for diabetic retina (left eye injected with scramble siRNA) versus normal retina;
#signiﬁcant decrease
(Po0.05, n¼3–4) in gene expression after TXNIP siRNA treatment (right eye) when compared with scramble scrRNA-treated diabetic eyes of the same animal. Some
retinas in siRNA-treated diabetic rats showed too low expression (Ct, N/A) under these experiments and were excluded in the analysis. (d) TXNIP mRNA silencing also
reduces GFAP expression in the diabetic retina when compared with the scr-siRNA-treated diabetic retina. A representative of n¼3 is shown here
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Cell Death and Diseaseof silencing TXNIP individually. In this study, we used a
combination of both promoter-siRNAs and demonstrate the
feasibility of this approach in the retina in vivo. In addition, we
show that CPPs are excellent agents for bioactive siRNA
delivery in the retina, which in combination with RNAi TGS
open the way for a new gene therapy approach to prevent
diabetic ocular complications. RNAi TGS method will provide
an alternative option for gene therapy in addition to viral-
mediated gene delivery/silencing because CPPs do not
perturb host genome. Viral vectors need to be incorporated
in to host chromosome and they may introduce random
mutations as viral DNA cannot be speciﬁcally targeted. In
addition, viral DNAs may evoke host innate immunity and
inﬂammation. For these considerations, we undertook the
CPP-mediated RNAi TGS route to suppress TXNIP in DR.
Intravitreal injection of CPPs have been used to drive siRNAs
and proteins into the retina of rodents both in Muller glia and
ganglion cells without affecting the retinal function.
32,33
Therefore, we expect that intravitreal injection of MPG RNAi
complex used in this study targets both Muller glia and
ganglion cells as gliosis and apoptosis are reduced by the
TXNIP promoter-siRNA.
Several studiesincluding our own show thatTXNIP induces
oxidative stress and inﬂammation in various cell types.
34,35
However, we previously demonstrated that TXNIP also
induces inﬂammation without detectable ROS in cells and
TXNIP-dependent Cox-2 mRNA expression is not affected by
the antioxidant a-lipoic acid.
14 Therefore, TXNIP-mediated
inﬂammation itself can induce retinal oxidative and nitrosative
stress in diabetes.
36 TXNIP upregulation leads to epigenetic
modiﬁcation of the Cox-2 promoter and involves alternative
histone H3K9 acetylation/methylation.
14 We did not investi-
gate here TXNIP-induced epigenetic modiﬁcation of the
Cox-2 and FN promoters in the diabetic rat retina in vivo,a s
well as the role of oxidative stress in TXNIP-mediated
inﬂammation, ﬁbrosis and neuronal apoptosis. Herein, we
focus our attention to demonstrate ﬁrst that TXNIP has a
causative role inthe development of early DR. We extensively
show that a blockade of TXNIP expression in the diabetic rat
retina inhibit the early abnormalities of DR.
Figure 5 TXNIPTGSby promoter-targetedsiRNAs inhibitsinﬂammation and ﬁbrosisin the diabeticretina.(A)MessengermRNAlevels were analyzedby RT-qPCRafter
diabeticrats weretreatedwith TXNIPpromoter-siRNAsviaintravitrealinjectionusingCPPsascargocarriers.TXNIPmRNAlevelsaresigniﬁcantly(
#Po0.05,n¼6)reduced
inthediabeticratretina(righteye)afterTXNIPTGSascomparedwiththelefteyeofthesameanimalthatreceivedascramblesiRNA.Similarly,TXNIPpromoter-siRNAsalso
signiﬁcantly blocks Cox-2 and FN expressions (
#Po0.05, n¼6) when compared with the scr-siRNA-treated retina of the same animal. *Po0.05 represents signiﬁcant
increaseingeneexpressionversusnormalretina.(B)ChIPanalysisofp300bindingtoTXNIPpromoterdemonstratesthatdiabetesincreasesp300bindingtoTXNIPpromoter
and TXNIP TGS prevents p300 binding to TXNIP promoter as revealed by qPCR of the ChIP DNA with TXNIP promoter primers (n¼3 performed in duplicates). No p300
bindingtoTXNIPwasobservedin normalretina.(C)Promoter-siRNAstargetedto TXNIPgenein thediabeticretinadownregulatesTXNIPproteinexpression(A,right panel),
which is comparable more or less to the level of age-matched nondiabetic rats (representative of three independent experiments)
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inﬂammation and neurovascular injury in DR. TXNIP provides
an excellent target for gene and drug therapies to prevent
ocular complications of diabetes. Further long-term studies
are warranted to establish the role of TXNIP in pathoetiology
of DR and therapeutic potentials of RNAi TGS.
Materials and Methods
Materials. Antibody for TXNIP was purchased from MBL Biotechnology
(Woburn, MA, USA), while CTD110.6 and Cox-2 antibodies were from Abcam
(Cambridge, MA, USA). Antibodies for modiﬁed histones were also obtained from
Abcam. a-Tubulin and actin were also obtained from Cell Signaling Solutions (Lake
Placid, NY, USA). Fluorescent-labeled mouse anti-GFAP antibodies conjugated
with Alexa Fluor 488, Nissl stain, and ﬂuorescent secondary antibodies for mouse
andrabbit werepurchasedfrom MolecularProbes(Invitrogen, Carlsbad,CA,USA).
The enhanced chemiluminescence (ECL) system was purchased from Amersham
(Arlington Heights, IL, USA). DMEM and F-12 nutrient mixture (Ham’s) were from
GIBCO (Grand Island, NY, USA).
Cell culture. In this study, we used a conditionally immortalized temperature-
sensitive rat retinal EC line, TR-iBRB2, as recently described.
14 Brieﬂy, these cells
Figure 6 TXNIP TGS by promoter-targeted siRNAs inhibits GFAP and caspase-3 activation in the diabetic retina. (a–b) TXNIP TGS by promoter-siRNAs also reduces
GFAP mRNA (a) and protein expression (b) in the diabetic retina (right eye) when compared with scr-siRNA-treated diabetic retina (left eye) of the same animal. *Signiﬁcant
change (Po0.05, n¼5–6) in GFAP expression for diabetic retina (left eye injected with scramble siRNA) versus normal retina;
#signiﬁcant decrease (Po0.05, n¼5–6) in
GFAPgeneexpressionafterTXNIPsiRNAtreatment(righteye)whencomparedwithscramblescr-RNA-treateddiabeticeyesofthesameanimal.Arepresentativeofn¼3is
shown here of the GFAP immunohistology. (c) Further, TXNIP TGS also reduces diabetes-induced caspase-3 activation in the GCL (right eye, as shown by an arrow) when
compared with left eye (diabetic control injected with scr-siRNA) in the GCL. A representative of n¼3 is shown here
Figure 7 A representative scheme of TXNIP-induced retinal inﬂammation,
ﬁbrosis/gliosis and ganglion injury in early DR. HBP is elevated early in the retina
STZ-inductiondiabeticratsandisresponsibleforTXNIPexpression.Recruitmentof
p300 on TXNIP promoter is involved in TXNIP expression. Ablation of TXNIP
inhibits inﬂammatory gene expression for Cox-2 and FN, gliosis and neuronal injury
in early diabetic retinas in vivo
TXNIP mediates early abnormalities of diabetic retinopathy
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Cell Death and Diseasemaintain spindle ﬁber shapes, multicellular nodules and exhibit bipolar morphology
liketheprimaryretinalECs.TR-iBRB2cellsexpressendothelialmarkers,suchasvon
Willebrand factor, acetylated low-density lipoprotein receptors, VEGF receptor 2
(KDF/Flk-1), glucose transporter Glut-1 and maintain other endothelial properties.
14
The TR-iBRB2 cells were maintained at 331C in DMEM and F-12 Nutrient Mixture
(Ham’s) (4:1 ratio) containing a normal D-glucose concentration of 5.0mM, 10%
FCS, 100mg/ml treptomycin, 100U/ml penicillin and 2mM glutamine. After the
cells reach 70–80% conﬂuence, they were differentiated at 371C in a humidiﬁed
incubator of 5% CO2 and then incubated in the starvation medium with the desired
concentrations of glucose (5mM, LG or 25mM, HG) or GlcN (1.5mMþLG) for
different time periods. When azaserine (an inhibitor of HBP pathway, 0.5mM) (from
Sigma,St.Louis,MO,USA)wasaddedtotheculture,theywereintroduced1hbefore
adding glucose and were present throughout the period of incubation. Inhibitors for
p38 MAPK and NF-kB were purchased from Calbiochem (San Diego, CA, USA).
Generation of stably transfectant TR-iBRB2 cell lines. The
CMV-human TXNIP and CMV-LacZ in pcDNA3.1 plasmid were used to generate
stably overexpressing TXNIP and corresponding control LacZ cell lines as
previously described.
11 To knock down TXNIP expression, we performed four
independent transfections with four different plasmids carrying a double-stranded
oligonucleotide targeted to different regions of the rat TXNIP mRNA (Super Array
Bioscience Corporation, Frederick, MD, USA), as recently described.
14 As control,
a plasmid encoding a scramble RNA was transfected. The clone that strongly
silencedTXNIPexpressionwasidentiﬁedbyreal-timequantitativePCR(qPCR)and
western blot analysis.
Reverse transcriptaseqPCR. mRNAexpressionwereanalyzedbyreverse
transcriptase (RT)-qPCR using the BioRad Chromo 4 detection system (BioRad,
Hercules, CA, USA) and SYBR Green PCR Master Mix from Applied Biosystems
(Foster City, CA, USA) as previously described.
11,14 Primers were synthesized by
Invitrogen.
Primer sequences of genes for the RT-qPCR are the following:
1. Rat TXNIP: Forward: 50-GTGAAGTTACCCGAGTCAAAGC-30
Reverse: 50-CTCACCTGTAGGCTGGTCTTCT-3
2. mFibronectin: Forward: 50-CTGGGGTCA CGTACCTCTTCA-30
Reverse: 50-AGTCGGTAGCCTGCTATACGG-30
3. Rat Cox-2: Forward: 50- TACCCGGACTGGATTCTACG- 30
Reverse: 50- AAGTTGGTGGGCTGTCAATC-30
4. Rat GFAP: Forward: 50-GAGGAGATCCAGTTCTTGAGG-30
Reverse: 50-CGTACTGAGTGCGAATCTCTC-30
5. mActin: Forward: 50- ATTATCACCAACTGGGATGACATGG -30
Reverse:50-CCAGCAGATTCCATACCAATGAAAG-30
Cycle threshold (Ct) values were used to calculate the relative expression level of
the various mRNAs that were normalized to actin mRNA. Primers for FN and actin
areformouseandalsoreactwithratgenes.Asnegativecontrols,thesamereaction
was performed on RNA samples without the reverse transcriptase reaction, and no
PCR products were detected.
ChIPfromretinalECs. ChIPisawidelyutilizedmethodtodetecttranscription
factor binding to speciﬁc DNA sequences or gene promoters in a chromatic
complex. We used EZ-ZymeTM Enzymatic Chromatin Prep Kit from Upstate (now
Millipore Corp., Billerica, MA, USA), which produces enzymatic cleavage of DNA to
180–360bp, as described recently.
14 Cells were ﬁxed in 1% ﬁnal parafolmaldeide
for 10min. Chromatin was obtained according to the manufacturer instructions.
Antibodies to AcH4K8 (Abcam), acetylated H3K9 and phosphorylated in Ser10,
trimethylated H3K9
14 and p300 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
were used at 1:100 dilution. The proximal promoter regions for TXNIP, Cox-2 and
FN were analyzed by qPCR and semiquantitative PCR using the following primers:
1. TXNIPC1F: 50-CCCGAACAACAACCATTTTCC-30
TXNIPC1R: 50-TTATATAGCCGCCTGGCTTG-30
2. Cox-2 promF: 50-CAGCAGCCCTCTCATTTCATT-30
Cox-2 promR: 50-TCTTTGAGGTCTCGGGTTTCC-30
3. FNpromF: 50-CGGACTCCGGCCAATCGGC-30
FNpromR: 50-GTGCAGTGCAGCGGGTGCG-30
ChIP from the rat retina. We optimize a ChIP method for TXNIP promoter
analysis from the frozen rat retina. Brieﬂy, one frozen retina was ﬁxed for 30min in
1% paraformaldehyde (PFA) in PBS on ice. Tissue was dispersed with a hand-held
homogenizer and further ﬁxation of retinal tissue was continued for an
additional 30min on ice. Chromatin was puriﬁed using the Nuclear Extraction Kit
(ActiveMotif,Carlsbad,CA,USA;catalognumber40010).Immunoprecipitationwas
carried out using the Immunoprecipitation Kit-Dynabeads-Protein A (Invitrogen,
catalog number 100.07D); the rabbit anti-p300 polyclonal antibody was used at
1:100 dilution for 16h. Dynabeads were added for further 2h. Beads were
resuspended in 0.1ml TE buffer (10mM Tris/Cl pH 8; 1mM EDTA) and treated for
30min with RNase 50mg/ml at 371C. Reversion of the crosslinking was carried out
byaddingproteinaseK500mg/mlandSDS0.5%for3hat441Candfurtherat651C
overnight.
14 DNA was extracted using the ChargeSwitch gDNA Micro Tissue kit
(Invitrogen, catalog number CS11203) and eluted from the magnetic beads in 60ml
of elution buffer. The promoter region for TXNIP (regions  478 and  297) was
analyzed by qPCR using the following primer pair as in ECs:
TXNIPC1F: 50-CCCGAACAACAACCATTTTCC-30
TXNIPC1R: 50-TTATATAGCCGCCTGGCTTG-30
SDS-PAGE and western blotting. SDS-PAGE and western blot analysis
of proteins were performed as described.
14 The primary antibodies were used at a
1:1000 dilution (unless otherwise mentioned) in Tris-buffered saline (pH 7.4)
containing 5% nonfat dry milk or 3% BSA. The dilution for HRP-conjugated
secondaryantibodieswasintheproportionof1:3000(v/v).ECLwasusedtodetect
the immunoreactive bands.
Diabetes induction of rats. Diabetes of adult male Sprague–Dawley rats
(B275g) was induced by injection of a single dose of STZ, (65mg/kg i.v., Sigma)
dissolved in 0.01M citrate buffer, pH 4.5. Normal rats received a similar volume of
vehicle alone. The rats were treated in accordance with the principles of NIH
guidelines for the Care and Use of Laboratory Animals and approved by the
Institutional Animal Care and Use Committee. Before starting the experiments, the
rats were acclimatized for 1 week. Diabetes was established after 48h of STZ-
injection and considered as day 1 of diabetes in rats. The treatment conditions
and characterization of the diabetic rats are shown in Supplementary Table 1.
At 4 weeks, diabetes rats have a blood glucose level of B500mg per 100ml
compared with B102mg per ml in control rats. Diabetic rats were given 1–2U of
insulin (Humulin-N, Lilly, Indianapolis, IN, USA) to maintain body weight in alternate
days or daily, dependingon the blood glucose levels as monitored by a glucometer.
Intravitreal injection of azaserine (2.5mlo f1 0 mM azaserine) was performed in
anesthetized rats with 40mg/kg body weight on the right eyes of diabetic rats
(treatment)andasimilarvolumeofsalineonthelefteye(control).Thebloodlevelof
glucose stays elevated after this treatment (Supplementary Table 1). The injections
wereperformedtwiceatdays23and27andtheywerekilledatday30.Anoverdose
ofpentobarbital(200mg/kgweight)wasgiventoeuthanizetherats.Theretinawere
removed, processed for immunohistological analysis or frozen immediately in liquid
N2 and stored at  801C until used.
TGS for TXNIP by promoter-targeted siRNAs in the diabetic rat
retina. As epigenetic TGS by chromatin reprogramming in vivo is a new
technique for gene silencing in mammals, we provide a brief background of the
process below.
(I) TXNIP promoter-siRNA targets: Short duplex small inhibitory RNAs (siRNAs)
can target mRNAs and inhibit translation by mRNA degradation, which is known as
PTGS. This method for blocking mRNA translation has become the commonly
employed method for gene silencing. On the other hand, TGS caused by antigene
siRNAs has been known for several years in the plant and lower animals. However,
until recently it remained unknown whether siRNA-mediated TGS occurs in
mammals. It has been demonstrated that the antisense strand of double-stranded
RNAi targeted toward the promoter leads to an assembly of repressor complexes
containing argonaute 1, histone deacetylase HDAC-1, H3K9 dimethyltransferase
G2a and DNA methyltransferase DNMT3a without cleaving the DNA.
30,37,38 This
assembly leads to H3K9 dimethylation, chromatin condensation and induces gene
silencing.Theadvantageof TGSover PTGSisthatit tacklestherootcauseof gene
TXNIP mediates early abnormalities of diabetic retinopathy
L Perrone et al
9
Cell Death and Diseaseexpression and has the potential to correct aberrant gene expression directly
while PTGS is a secondary remedy. Therefore, we developed this novel technique
for epigenetic gene silencing for TXNIP in the retina of diabetic rats using the
following promoter targets.
(i). TXNIP Promoter Target 1: 50-AATGGTCACGTCGAAATGAAT-30
siRNAs: sense: 50-UGGUCACGUCGAAAUGAAUTT-30
antisense: 50-TTACCAGUGCAGCUUUACUUA-30
(ii). TXNIP promoter target 2. 50-AACTGTGCACGAGGGATGCAC-30
siRNAs: sense: 50-CUGUGCACGAGGGAUGCACTT-30
antisense: 50-TTGACACGUGCUCCCUACGUG-30
These double-stranded siRNAs targeting the rat TXNIP promoter (UniGene:
Rn.2758, NCBI Entrez) at (i)  413 to  434 (PromoterTarget 1) and(ii)  8t o 29
(Promoter Target 2) from the transcription start site (TSS þ1) were custom
synthesized by Applied Biosystems (Ambion).
(II) CPPs as promoter-siRNA transducting agents: In order to drive these TXNIP
promoter-siRNAs to cell nucleus in the retina of diabetic rats, we chose recently
developed CPPs as cargo carriers. Recent advances have been developed in the
employment of CPPs for siRNA delivery to mammalian cells, particularly to cell
nucleus, which mediates epigenetic gene silencing by chromatin reprogramming.
19
This is a very attractive approach for ocular disease treatment in diabetes. The
potential advantage of this delivery system is that they penetrate the cell
membranes carrying the cargos (nucleic acids or protein) into the nucleus in
nondividing fully differentiated cells. These peptides are usually o40 amino acids
and have three components: (i) an N-terminus hydrophobic amino acid sequence;
(ii)aC-terminusnuclearlocalizationsignal;and(iii)alinkerdomainbetweenthetwo
regions.In thisstudy, weused an siRNA-transducingCPPknown asMPG.
30,39 The
amino-acid sequence of MPG is as follows:
MPG (27 residues): Acetyl-GALFLGFLGAAGSTMGAWSQPKKKRKV-
cysteamide
MPG was custom synthesized by Anaspec (San Jose, CA, USA). The linker portion
is shown in bold and the nuclear localization sequence in italics. The peptide is
acetylated at N-terminus and carries a cysteamide group at the C-terminus, which
enhance peptide stability and efﬁciency in transduction. The N-terminus of MPG
is derived from HIV glycoprotein 41 (gp41) for membrane penetration and the
C-terminus is the NLS of SV40 large T-antigen.
39
(III) Intravitreal injection of MPG and promoter-siRNA complex in
theratretina. Alltheproceduresare performedinasterile BSL2facilityundera
dissecting microscope. Brieﬂy, under anesthesia (40mg/kg pentobarbiatal), a small
puncture is made in the eye with a single-use monojet 250 needle. To analyze the
efﬁcacy of this method, we tested several concentration ranges for TXNIP silencing
using two promoter-targeted siRNAs together in rat retinal ECs in culture.
MPG:prom-siRNA molar ratio of 10:1 at 40–100nM siRNA concentrations causes
a signiﬁcant silencingof TXNIP mRNA(B70%) at 24–72h (data notshown). Then,
2ml of a preformed MPG/siRNA complex at 10:1 molar ratio containing 2mM
siRNA(30min incubationat room temperaturebefore the injections)was injectedin
the vitreous through the limbus using a 10ml nanoﬁl syringe and a ﬁne 35-gauge
needle (WPI, Sarasota, FL, USA). The TXNIP Prom-siRNA injections were
performed on the right eye (treatment) and scramble siRNAs on the left eye (RNAi
Negative Control Duplex; Invitrogen, catalog number 1295112 Medium GC) of the
same animal. Injections were performed twice at days 16 and 20 on each retina in
order to establish a stable chromatin remodeling.
PTGS for TXNIP in the diabetic rat retina. Rat TXNIP mRNA siRNAs
(#1330001, RSS332043) and Negative Control Duplexes (#12935-300) were
purchased from Invitrogen. MPG-dNSL (27 residues): We used a C-terminus modi-
ﬁed MPG at NSL called MPG-dNSL – (27 residue): acetyl-GALFLGFLGAAG
STMGAWSQPKSKRKV-cysteamide. MPG-dNSL was also custom-synthesized by
Anaspec. Intravitreal injection of TXNIP siRNA (B100nM) and MPG-dNSL
complexes (10:1 ratio of MPG-dNSL:siRNA) was performed in anesthetized rats
with40mg/kgbodyweightontherighteyesofdiabeticrats(treatment)andasimilar
volume of MPG-dNSL in saline on the left eye (control). The injections were
performed twice at days 23 and 27 and they were killed at day 30 similar to
azaserine treatment. An overdose of pentobarbital (200mg/kg weight) was given to
kill the rats. The retina were removed, processed for immunohistological analysis or
frozen immediately in liquid N2 and stored at  801C until used.
Immunohistochemistry. Immunohistological methods were similar those
described recently by Drs. Ivanova and Pan
40 as described in Supplementary
methods. The retinas were ﬁxed in the eyecups with 4% PFA in 0.1M phosphate
buffer (PB) for 20min. The retinas were cryoprotected in a sucrose gradient (10, 20
and 30% w/v in PB, respectively). Cryostat sections were cut at 20ı ´m in Tissue Tek
(VWR, Batavia, IL, USA) (OCT mounting medium). Retinal sections were blocked
for 1h in a PB solution thatcontained 5% Chemiblocker (Chemicon, Temecula,CA,
USA), 0.5% Triton X-100 and 0.05% sodium azide. The primary antibodies were
diluted in the same solution (1:200 to 1:400 dilution depending on the antibody)
and applied overnight followed by appropriate secondary antibodies (1:600
dilutions) conjugated with Alexa Fluor 488 or Alexa Fluor 594 for 2h. The images
were captured by an OLYMPUS BX 51 ﬂuorescence microscope (Center Valley,
PA,USA),whichisﬁttedwithatripleDAPI/FITC/TRITCcube,aDP70digitalcamera
and image acquisition software. Some images were also captured with a Zeiss
Apotome microscope with Z-section (Zeiss, Oberkochen, Germany). Similar
magniﬁcation ( 400) and exposure time were maintained throughout for
comparing images unless otherwise mentioned.
In vivo caspase-3 activation assay using FAM-FLIVO reagent. We
used green Flivo as an in vivo reagent to detect activated caspase-3 inintact animals
according to manufacturer’s instruction (Immunohistochemistry Technologies,
Bloomington, MN, USA). Flivo is cell and blood–retinal barrier permeable and binds
covalently to active caspase-3 giving green ﬂuorescence undergoing apoptosis.
Underdeepanesthesia,150mloftheFlivoreagentwasinjectedinthetailvein30min
before euthanization. Atthe end of30min,additionalanesthesiawas appliedand the
chest cavity in cells was opened; a small cut was made in the atrium to drain blood.
Asmallcutwasthenmadeattheleftventricleand20mlofsalinewasinjectedtoﬂush
blood and retina was removed quickly. Retinal was ﬁxed in 4% PFA for 20min and
processed for retinal ﬂat mount or cryosectioning in OCT. This is the ﬁrst
demonstration of in vivo caspase-3 activation assay in the retina. Furthermore, FAM-
Flivomethodfordetectingactivatedcaspase-3invivowasconﬁrmedbyusingNMDA-
inducedexcitotoxicity and ganglioncelldeath inrat retinas(DrD Goebel, Department
of Anatomy and Cell Biology, Wayne State University, Detroit, MI, USA (personal
communication)).
Statistical analysis. Results are expressed as means±S.E. of indicated
number of experiments. Comparison between two sets of experiments was analyzed by
Student’s t-test while one-way ANOVA was used to determine differences among means
inmultiplesetsofexperimentsfollowedbyBonferroniposthoctest.Inbothcases,apreset
P-value of o0.05 was considered statistically signiﬁcant.
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